$18.520
-0.506 (-2.73%)收盘时
TYRA 资讯
TYRA 事件
Tyra Biosciences Prices 9.079 Million Share Offering at $22.03, Raising Approximately $400 Million
Tyra Biosciences announced the pricing of an underwritten offering of 9,079,000 shares of its common stock at a price of $22.03 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 9,078,529 shares of common stock at a purchase price of $22.029 per share, which equals the offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. All of the shares of common stock and pre-funded warrants in the offering are being sold by Tyra. The gross proceeds to Tyra from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $400.0 million. The offering is expected to close on September 15, 2026. TYRA intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to advance its "dabogratinib 3x3" development strategy in low-grade upper tract urothelial carcinoma (LG-UTUC), intermediate-risk non-muscle invasive bladder cancer (IR NMIBC) and achondroplasia, as well as to support its preclinical and drug discovery programs, working capital and other general corporate purposes. The offering was led by RA Capital Management, with participation by new and existing institutional investors, including Invus, Commodore Capital, BVF Partners, Janus Henderson Investors, Trails Edge Capital Partners, Integral Health Asset Management, TCGX, StemPoint Capital LP and multiple large investment management firms.
Tyra Biosciences Files Automatic Mixed Securities Shelf
Tyra Biosciences files automatic mixed securities shelf
Major Averages Decline for Second Day as Treasury Yields and Oil Prices Rise
The major averages moved lower for a second day in a row as Treasury yields and oil prices continue to climb. Treasury yields jumped after the U.S. Treasury Department said it will triple its buyback operation of longer-dated government debt to $6B.The renewed oil spike, meanwhile, is being driven by escalating fighting in the Middle East, including attacks involving Iran-backed Houthi militants and Saudi energy infrastructure. Brent has gained roughly 20% over the past month, raising concerns that an extended energy shock could feed directly into consumer inflation and complicate the Federal Reserve's policy decision next week.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Independence Realty Trustand Centerspacein an $8.1B all-stock combinationAnalog DevicesAlif Semiconductor for $1.35B in cashJersey Mike's Subsreportedin its first quarterly report as a public companyChimeStride Bank for $590M in cash and raised its Q3 and FY26 revenue outlooksDuring a live-streamed event, Appleunveiled its new, as well as the iPhone 18 Pro, AirPods 5, and two new Apple Watches2. WALL STREET CALLS:Thermo Fisherto Buy at UBSDyne Therapeuticsto Underweight at JPMorganLineageto Overweight at Morgan StanleyMartin Mariettato Overweight at Wells FargoVulcan Materialsto Underweight at Wells Fargo3. AROUND THE WEB:UnitedHealthis selling a stake in Optum Health to TPGoperations as it works to restructure and stabilize the underperforming division following a major profit decline, Bloomberg reportsBP'sNorth Sea operations have drawn interest from suitors including Adura and NEO Next+, Bloomberg saysAs part of efforts to reshape its portfolio amid a prolonged downturn in the industry, Dowis considering plans to exit its $20B chemicals partnership with Saudi Aramco, Bloomberg reportsParamount Skydanceis arguing that California AG Rob Bonta's public comments undermine his legal opposition to Paramount's $1.88B bond request, potentially strengthening its position as it seeks protection against costs from the state-led challenge to its Warner Bros. Discoverymerger, Reuters saysThe U.S. Justice Department is expanding its antitrust probe into Fox'sproposed $22B takeover of Roku, Semafor reports4. MOVERS:Opus Geneticsgained afterof its BIRD-1 trialSignet Jewelersincreased in New York after, providing guidance for Q3, and raising its outlook for FY27Compass Pathwayswas higher in New York afterfrom its Phase 3 COMP005 trialServiceTitanfell afterand appointing Pretorius as its next chief revenue officerTyra Bioscienceswas lower after reporting results from its5. EARNINGS/GUIDANCE:Academy Sportsand raised its outlook for FY26Core & Main, with CEO Mark Witkowski commenting that "momentum continues to build across the business"Chewy, provided guidance for Q3, and raised its outlook for FY26Sunbelt Rentals, with EPS and revenue beating consensusCognyte, with CEO Elad Sharon calling it "a strong quarter"INDEXES:The Dow fell 405.41, or 0.77%, to 52,380.66, the Nasdaq lost 168.07, or 0.64%, to 26,253.34, and the S&P 500 declined 37.16, or 0.48%, to 7,636.36.
Major Averages Decline for Second Day as Treasury Yields Rise
The major averages were broadly lower for a second day in a row as Treasury yields continue to climb and oil prices rise towards the $100 per barrel mark. Treasury yields jumped after the U.S. Treasury Department said it will triple its buyback operation of longer-dated government debt to $6B.The renewed oil spike, meanwhile, is being driven by escalating fighting in the Middle East, including attacks involving Iran-backed Houthi militants and Saudi energy infrastructure. Brent has gained roughly 20% over the past month, raising concerns that an extended energy shock could feed directly into consumer inflation and complicate the Federal Reserve's policy decision next week.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Independence Realty Trustand Centerspacein an $8.1B all-stock combinationAnalog DevicesAlif Semiconductor for $1.35B in cashJersey Mike's Subsreportedin its first quarterly report as a public companyChimeStride Bank for $590M in cash and raised its Q3 and FY26 revenue outlooksApplewillat 1:00 pm ET Wednesday, where it is reportedly expected to unveil a foldable iPhone duo2. WALL STREET CALLS:Thermo Fisher (TMO)to Buy at UBSDyne Therapeuticsto Underweight at JPMorganLineageto Overweight at Morgan StanleyMartin Mariettato Overweight at Wells FargoVulcan Materialsto Underweight at Wells Fargo3. AROUND THE WEB:UnitedHealthis selling a stake in Optum Health to TPGoperations as it works to restructure and stabilize the underperforming division following a major profit decline, Bloomberg reportsBP'sNorth Sea operations have drawn interest from suitors including Adura and NEO Next+, Bloomberg saysAs part of efforts to reshape its portfolio amid a prolonged downturn in the industry, Dowis considering plans to exit its $20B chemicals partnership with Saudi Aramco, Bloomberg reportsParamount Skydanceis arguing that California AG Rob Bonta's public comments undermine his legal opposition to Paramount's $1.88B bond request, potentially strengthening its position as it seeks protection against costs from the state-led challenge to its Warner Bros. Discoverymerger, Reuters saysThe U.S. Justice Department is expanding its antitrust probe into Fox'sproposed $22B takeover of Roku, Semafor reports4. MOVERS:Opus Geneticsgains afterfrom its low-dose Cohort 1 of its BIRD-1 trialSignet Jewelersincreases in New York after, providing guidance for Q3, and raising its outlook for FY27Compass Pathwayshigher in New York after reporting 52-week results from itsServiceTitanfalls afterand appointing Pretorius as its next chief revenue officerTyra Bioscienceslower after reporting results from itsof SURF3025. EARNINGS/GUIDANCE:Academy Sportsand raised its outlook for FY26Core & Main, with CEO Mark Witkowski commenting that "momentum continues to build across the business"Chewy, provided guidance for Q3, and raised its outlook for FY26Sunbelt Rentalswith EPS and revenue beating consensusCognyte, with CEO Elad Sharon calling it "a strong quarter"INDEXES:Near midday, the Dow was down 397.03, or 0.75%, to 52,389.04, the Nasdaq was down 163.49, or 0.62%, to 26,257.92, and the S&P 500 was down 34.16, or 0.45%, to 7,639.36.
Brent Crude Surpasses $100, Heightening Market Concerns
Stocks are lower as Brent crude rises above $100 a barrel for the first time since July, adding to inflation concerns ahead of this week's key price data. Additionally, the 10-year Treasury yield has climbed to around 4.81%, its highest level in nearly three years.The renewed oil spike is being driven by escalating fighting in the Middle East, including attacks involving Iran-backed Houthi militants and Saudi energy infrastructure. Brent has gained roughly 20% over the past month, raising concerns that an extended energy shock could feed directly into consumer inflation and complicate the Federal Reserve's policy decision next week.That puts Thursday's PPI and Friday's CPI reports firmly in the spotlight. Markets are currently pricing roughly a 62% probability of a 25-basis-point Fed rate hike next week, according to CME FedWatch, a shift from earlier expectations for easier policy. A hotter-than-expected inflation reading could push yields and rate-hike expectations even higher, while a benign report could give stocks some relief despite elevated oil prices.Meanwhile, investors will be watching Apple's iPhone 18 launch event later today to see whether the company introduces meaningful hardware or pricing changes under new CEO John Ternus, particularly amid reports of a potential foldable iPhone.In pre-market trading, S&P 500 futures fell 0.33%, Nasdaq futures fell 0.49% and Dow futures fell 0.57%.Check out this morning's top movers from around Wall Street, compiled by The Fly.UP AFTER EARNINGS -Oddityup 32%J.Jillup 14%Signet Jewelersup 9%Caleresup 7%InnovAgeup 7%Jersey Mike's Subsup 1%Chewyup 1%DOWN AFTER EARNINGS -ServiceTitandown 19%Casey's General Storedown 11%SailPointdown 7%LOWER -Tyra Biosciencesdown 25% after reporting initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。